Xultophy Phase 3b study showed statistically significant HbA1c reduction, body weight change and lower rate of hypoglycaemia versus insulin glargine
8 June 2015 | By Victoria White
Phase 3b findings show adults with T2D treated with Xultophy demonstrate statistically significant reduction in HbA1c and a lower rate of hypoglycaemia...